Inhibiting NF-κB/IKK2 using PLGA polymer-packed small molecular chemical inhibitors could be a potential therapeutic approach for treating the inflammation and angiogenesis-associated eye diseases. This evidence concerns the gene NFKB1 and eye disorder.